Oxfordshire Clinical Commissioning Group Formulary

	Oxfordshire Clinical Commissioning Group
	Formulary

Search

Formulary Chapter 3: Respiratory system - Full Chapter

Chapter Links...

BTS/SIGN Asthma Guideline Quick Reference Guide 2016

MHRA Safety Alerts: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects

NICE CG101: COPD guideline

NICE TA10: Asthma inhaler devices (children under 5)

NICE TA38: Asthma inhaler devices (older children)

OCCG Guidelines: COPD Management in Primary care — Inhaled Therapies

OCCG Guidelines: Maintenance Management of Asthma – Inhaled and Oral Therapies (adults)

OUH Leaflet: Pulmonary Rehabilitation patient leaflet

UKMI Q&A: Nebuliser compatibilities

Details...

03.01.01.01

Selective Beta₂ agonists

MHRA review: Formoterol and salmeterol in asthma & COPD

03.01.01.01

Short-acting beta₂ agonists

03.01.01.01

Long-acting beta₂ agonists

Formoterol fumarate (Oxis^® Turbohaler)

Formulary

For COPD patients use Oxis® 12 Turbohaler in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

Olodaterol (Striverdi Respimat^®)

Formulary

In line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

Formoterol Fumarate (Atimos^® Modulite)

Restricted

Atimos® should not be initiated for new patients for COPD or asthma.

People whose treatment with Atimos® is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

Formoterol fumarate (Easyhaler 12micrograms/dose)

Restricted

Formoterol Easyhaler® should not be initiated for new patients for COPD or asthma.

People whose treatment with Formoterol easyhaler® is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

Salmeterol

Restricted

Salmeterol 25mcg should not be initiated for new patients for COPD or asthma.

People whose treatment with Salmeterol 25mcg is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

....

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG

Traffic Light Status Information

Status	Description
	Red: Medicines which should only be prescribed in secondary care by a specialist.
	Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.
	Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).
	Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.
	Brown: Medicines which should only be prescribed in restricted circumstances.
	Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.
	not used